Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 1 Interventional

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

NCT01529437
View directory record Official record
Conditions
Allergies, Allergic Rhinitis, Asthma
Interventions
sublingual immunotherapy, placebo sublingual immunotherapy
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

NCT00453375
View directory record Official record
Conditions
Diabetes, Hypoglycemia
Interventions
BHT-3021, BHT-Placebo
Drug
Lead sponsor
Bayhill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression

NCT01683019
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
NeoSync EEG Synchronization Therapy, Sham NeoSync EEG Synchronization Therapy
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 3 Interventional Results available

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

NCT01227512
View directory record Official record
Conditions
Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
Interventions
tolvaptan, Fluid Restriction
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 17, 2026, 12:23 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

NCT05006430
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Prasun Kumar Jalal
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 17, 2026, 12:23 PM EDT
Withdrawn Not applicable Interventional

Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study

NCT00669799
View directory record Official record
Conditions
Rhinosinusitis
Interventions
gentamyacin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

NCT01122381
View directory record Official record
Conditions
Headache, Migraine
Interventions
ethosuximide, placebo comparator
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 4 Interventional Results available

Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

NCT04862234
View directory record Official record
Conditions
Hyperglycemia Stress
Interventions
Dulaglutide, Placebo, Continuous glucose monitor (CGM), blinded
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192
View directory record Official record
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flushes and Sertraline Trial

NCT00283192
View directory record Official record
Conditions
Menopause-Hot Flashes
Interventions
Sertraline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT02500381
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, SRP-4053, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 13 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Fluarix Immunogenicity and Safety Trial

NCT00100399
View directory record Official record
Conditions
Influenza
Interventions
Fluarix
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

NCT04582409
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
HSY244, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

NCT00565214
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Group 1, Group 2
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 17, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

NCT07227948
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Semaglutide, Placebo, cognitive behavioral therapy (CBT).
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 12:23 PM EDT
Recruiting Phase 1 Interventional

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

NCT03860233
View directory record Official record
Conditions
Sleep Apnea, Sleep Apnea, Obstructive
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Vivek Jain
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

NCT03579459
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
1,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Redding, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

NCT00650754
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Unexplained Infertility
Interventions
Dehydroepiandrosterone, Placebo
Dietary Supplement · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 17, 2026, 12:23 PM EDT
Terminated Not applicable Interventional Results available

CASAD for Severe Diarrhea in the Emergency Department

NCT02018653
View directory record Official record
Conditions
Cancer, Diarrhea
Interventions
Calcium Alumina-Silicate (CASAD), Placebo, Questionnaire
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 17, 2026, 12:23 PM EDT